Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

667
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
667

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Donor-Related Factors Affecting Haploidentical HSCT Outcomes in Acute Leukemia: A Single-Center Retrospective Cohort Study of a Modified Combination of Anti-Thymocyte Globulin and Post-Transplant Cyclophosphamide.

Health science reports·2026
Same author

Establishment of Integrated Hospital-Based Supportive and Palliative Services: An Experience from Iran.

International journal of hematology-oncology and stem cell research·2026
Same author

Ex vivo evaluation of Newcastle disease virus to enhance natural killer cell function against acute myeloid leukemia cells.

Scientific reports·2026
Same author

Harnessing CAR-NK cells against multiple myeloma: current landscape and future directions.

Molecular biology reports·2026
Same author

Predictive factors for poor mobilization in autologous stem cell transplant: a multivariate model.

Hematology, transfusion and cell therapy·2026
Same author

MR-AIV reveals in vivo brain-wide fluid flow with physics-informed AI.

Science advances·2026
Same journal

TLR7/8 agonist 3M-052 formulated in micelles induces local type I IFN response and antiviral immunity in zebrafish larvae.

Frontiers in immunology·2026
Same journal

HLA-DRB1*15:01 drives sex- and age-dependent microglial immune phenotypes and neuroimmune signaling.

Frontiers in immunology·2026
Same journal

Gut microbiota transfer from autoimmune dry eye mice imprints stereotypic B cell receptor repertoires in the lacrimal gland and induces disease.

Frontiers in immunology·2026
Same journal

Exosomal microRNAs in colorectal cancer communication networks: implications for metastasis, therapy resistance, and precision medicine.

Frontiers in immunology·2026
Same journal

TMEM160 promotes hepatocellular carcinoma cell proliferation, invasion, and immune evasion by regulating the VEGFA/PI3K/AKT signaling axis.

Frontiers in immunology·2026
Same journal

Nurr1 deficiency orchestrates a coupled liver-gut pathological axis revealed by multi-omics and deep-learning histopathology.

Frontiers in immunology·2026
查看所有相关文章

相关实验视频

Updated: Sep 18, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.5K

全基性CART进展:平台,当前进展和局限性

Ameneh Shokati1, Maryam Sanjari-Pour2, Mahshid Akhavan Rahnama3

  • 1Department of Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Frontiers in immunology
|June 27, 2025
PubMed
概括
此摘要是机器生成的。

全基性CAR-T细胞比自身疗法具有优势,新技术改善了通用现成的选择. 这些进步解决了诸如移植与宿主疾病等未来癌症治疗的挑战.

关键词:
一种类型的CAR T细胞.编辑技术 编辑技术接种与宿主病的疾病.非编辑技术的非编辑技术现货的CART手机可以买到.

更多相关视频

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.3K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

811

相关实验视频

Last Updated: Sep 18, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.5K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.3K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

811

科学领域:

  • 免疫学 免疫学 免疫学
  • 在瘤学瘤学.
  • 生物技术是生物技术.

背景情况:

  • 基化学抗原受体T (CAR-T) 细胞对自身T细胞疗法具有明显的优势.
  • 这些好处包括改善细胞可用性,减少转导方法的风险,避免移植对宿主疾病 (GVHD) 和使用HLA匹配供体时的排斥.
  • 最近的技术进步,包括基因编辑和非编辑策略,对于实现全源CAR-T疗法的潜力至关重要.

研究的目的:

  • 审查最近在全源CAR-T细胞开发和临床应用方面的进展.
  • 突出普遍现成的CAR-T细胞在克服关键挑战方面的成功.
  • 总结过去十年对于血液性恶性瘤和癌症的临床前和临床研究结果.

主要方法:

  • 审查最近的科学文献和临床试验数据.
  • 对基CAR-T细胞的工程策略的分析.
  • 对治疗血液性恶性瘤和癌症的临床实践和结果的评估.

主要成果:

  • 工程和技术的改进正在使基CAR-T疗法变得更加可行.
  • 通用现成的CAR-T电池在解决GVHD和生产时间限制方面表现有前途.
  • 在最近的临床研究中,在血液恶性瘤和癌症中使用全原CAR-T细胞观察到显著的成功.

结论:

  • 全基性CAR-T细胞疗法,特别是通用现成产品,代表了癌症治疗的有希望的未来方向.
  • 持续的研究和技术创新对于优化全源CAR-T细胞的疗效和安全至关重要.
  • 在过去的十年中,在将异性CAR-T细胞应用于血液恶性瘤和癌症方面取得了实质性进展和成功.